Saudi Arabia medical cannabis market size share growth drivers trends opportunities & forecast 2025–2030

Saudi Arabia medical cannabis market, worth USD 302 million, is growing due to increasing acceptance of CBD and THC for medical applications like cancer and epilepsy.

Region:Middle East

Author(s):Geetanshi

Product Code:KRAD7895

Pages:93

Published On:December 2025

About the Report

Base Year 2024

Saudi Arabia medical cannabis market Industry Analysis

Growth Drivers

  • Increasing Global Research on Cannabis-Based Treatments:The global investment in cannabis research reached approximately $1.5 billion, with a significant portion directed towards medical applications. Saudi Arabia's healthcare sector is increasingly aligning with this trend, as evidenced by the establishment of research partnerships with international institutions. This collaboration aims to explore the therapeutic potential of cannabinoids, particularly in treating chronic pain and neurological disorders, thereby enhancing the local market's growth prospects.
  • Growing Awareness of Alternative Therapies for Chronic Illnesses:In Saudi Arabia, the prevalence of chronic diseases such as diabetes and hypertension is rising, affecting over 35% of the adult population. This has led to a growing interest in alternative therapies, including medical cannabis. As healthcare providers and patients seek effective treatment options, the demand for cannabinoid-based therapies is expected to increase, driving market growth and encouraging further research into their efficacy.
  • Rising Interest in Cannabinoid-Based Pharmaceuticals:The global cannabinoid pharmaceutical market is projected to reach $56 billion, reflecting a robust interest in cannabinoid-based medications. In Saudi Arabia, this trend is mirrored by the increasing number of clinical trials and product developments focused on cannabinoids. The Ministry of Health's support for innovative treatments is fostering an environment conducive to the growth of cannabinoid pharmaceuticals, which is expected to significantly impact the local market.

Market Challenges

  • Strict Legal Stance on Cannabis in Saudi Arabia:Saudi Arabia maintains a stringent legal framework regarding cannabis, with severe penalties for possession and use. The current laws classify cannabis as a controlled substance, limiting its availability for medical purposes. This legal environment poses a significant barrier to market entry for potential investors and pharmaceutical companies, hindering the development and distribution of cannabinoid-based products within the country.
  • Stigma Associated with Cannabis Use:Cultural perceptions of cannabis in Saudi Arabia remain largely negative, with significant stigma attached to its use. This societal attitude can deter patients and healthcare professionals from considering cannabis as a viable treatment option. The lack of public awareness and education regarding the medical benefits of cannabis further exacerbates this challenge, limiting market growth and acceptance of cannabinoid therapies in the healthcare system.

Saudi Arabia medical cannabis market Future Outlook

The future of the medical cannabis market in Saudi Arabia appears promising, driven by increasing research initiatives and a gradual shift in public perception. As global trends toward cannabis legalization and acceptance continue, local stakeholders are likely to advocate for regulatory reforms. This evolving landscape may lead to enhanced access to cannabinoid therapies, fostering innovation and collaboration within the pharmaceutical sector, ultimately benefiting patients seeking alternative treatment options for chronic conditions.

Market Opportunities

  • Development of CBD-Derived Medications and Pharmaceuticals:The growing global demand for CBD products, projected to reach $20 billion, presents a significant opportunity for Saudi Arabia. Local pharmaceutical companies can capitalize on this trend by developing CBD-derived medications, particularly for pain management and anxiety disorders, aligning with international market needs and enhancing local healthcare offerings.
  • Collaborations with International Research Institutions:Establishing partnerships with leading global research institutions can facilitate knowledge transfer and innovation in cannabinoid research. Such collaborations can enhance local capabilities in developing effective cannabinoid therapies, positioning Saudi Arabia as a regional hub for medical cannabis research and development, ultimately benefiting the healthcare system and economy.

Scope of the Report

SegmentSub-Segments
By Derivatives

Cannabidiol (CBD)

Tetrahydrocannabinol (THC)

Other Cannabinoids

By Application

Cancer

Epilepsy

Chronic Pain

Arthritis

Migraine

Other Neurological Disorders

By Route of Administration

Oral Solutions and Capsules

Vaporizers

Topicals

Other Routes

By Species/Formulation

Sativa

Indica

Hybrid

By End-User

Hospitals

Clinics

Research Institutions

Homecare

Others

By Distribution Channel

Pharmacies

Online Retail

Direct Sales

Others

By Geographic Region

Central Region

Eastern Region

Western Region

Southern Region

Others

Key Target Audience

Investors and Venture Capitalist Firms

Government and Regulatory Bodies (e.g., Saudi Food and Drug Authority, Ministry of Health)

Manufacturers and Producers

Distributors and Retailers

Pharmaceutical Companies

Healthcare Providers and Practitioners

Industry Associations

Financial Institutions

Players Mentioned in the Report:

Bedrocan (Netherlands-based medical cannabis producer)

Canopy Growth Corporation (Canadian cannabis company)

Aurora Cannabis (Canadian cannabis producer)

Tilray (Canadian cannabis and pharmaceutical company)

Cronos Group (Canadian cannabis company)

GlaxoSmithKline (Pharmaceutical company with cannabinoid research)

Insys Therapeutics (Cannabinoid-based pharmaceutical developer)

Zynerba Pharmaceuticals (CBD-focused pharmaceutical company)

Charlotte's Web Holdings (CBD product manufacturer)

Elixinol Global (CBD and hemp product company)

Kalytera Biosciences (Cannabinoid therapeutic developer)

Organigram Holdings (Canadian cannabis producer)

Aphria Inc. (Canadian cannabis company)

Medical Marijuana Inc. (Cannabis and CBD company)

Curaleaf (Cannabis retailer and producer)

Table of Contents

Market Assessment Phase

1. Executive Summary and Approach


2. Saudi Arabia medical cannabis market Overview

2.1 Key Insights and Strategic Recommendations

2.2 Saudi Arabia medical cannabis market Overview

2.3 Definition and Scope

2.4 Evolution of Market Ecosystem

2.5 Timeline of Key Regulatory Milestones

2.6 Value Chain & Stakeholder Mapping

2.7 Business Cycle Analysis

2.8 Policy & Incentive Landscape


3. Saudi Arabia medical cannabis market Analysis

3.1 Growth Drivers

3.1.1 Increasing Global Research on Cannabis-Based Treatments
3.1.2 Growing Awareness of Alternative Therapies for Chronic Illnesses
3.1.3 Rising Interest in Cannabinoid-Based Pharmaceuticals
3.1.4 Potential Regulatory Discussions Influenced by Evolving International Policies

3.2 Market Challenges

3.2.1 Strict Legal Stance on Cannabis in Saudi Arabia
3.2.2 Stigma Associated with Cannabis Use
3.2.3 Limited Direct Access to Medical Cannabis
3.2.4 Supply Chain Constraints for Cannabinoid-Derived Products

3.3 Market Opportunities

3.3.1 Development of CBD-Derived Medications and Pharmaceuticals
3.3.2 Expansion of Cannabinoid-Based Therapies for Epilepsy and Pain Management
3.3.3 Collaborations with International Research Institutions
3.3.4 Investment in Pharmaceutical Innovation and Clinical Evidence

3.4 Market Trends

3.4.1 Increasing Research and Development Activities on Medical Applications
3.4.2 Growing Demand for CBD Oil Among Wellness Consumers
3.4.3 Shift Towards Cannabinoid-Derived Pharmaceuticals Over Direct Cannabis Use
3.4.4 Rising Medical Professional Interest in Cannabis Efficacy Studies

3.5 Government Regulation

3.5.1 Current Prohibition on Cannabis Use with Potential Medical Exceptions
3.5.2 Quality Control Standards for Cannabinoid Products
3.5.3 Restrictions on Advertising and Promotion of Cannabis Products
3.5.4 Guidelines for Controlled Medical Access Under Strict Supervision

4. SWOT Analysis


5. Stakeholder Analysis


6. Porter's Five Forces Analysis


7. Saudi Arabia medical cannabis market Market Size, 2019-2024

7.1 By Value

7.2 By Volume

7.3 By Average Selling Price


8. Saudi Arabia medical cannabis market Segmentation

8.1 By Derivatives

8.1.1 Cannabidiol (CBD)
8.1.2 Tetrahydrocannabinol (THC)
8.1.3 Other Cannabinoids

8.2 By Application

8.2.1 Cancer
8.2.2 Epilepsy
8.2.3 Chronic Pain
8.2.4 Arthritis
8.2.5 Migraine
8.2.6 Other Neurological Disorders

8.3 By Route of Administration

8.3.1 Oral Solutions and Capsules
8.3.2 Vaporizers
8.3.3 Topicals
8.3.4 Other Routes

8.4 By Species/Formulation

8.4.1 Sativa
8.4.2 Indica
8.4.3 Hybrid

8.5 By End-User

8.5.1 Hospitals
8.5.2 Clinics
8.5.3 Research Institutions
8.5.4 Homecare
8.5.5 Others

8.6 By Distribution Channel

8.6.1 Pharmacies
8.6.2 Online Retail
8.6.3 Direct Sales
8.6.4 Others

8.7 By Geographic Region

8.7.1 Central Region
8.7.2 Eastern Region
8.7.3 Western Region
8.7.4 Southern Region
8.7.5 Others

9. Saudi Arabia medical cannabis market Competitive Analysis

9.1 Market Share of Key Players

9.2 Cross Comparison of Key Players

9.2.1 Company Name
9.2.2 Company Size (Large, Medium, or Small)
9.2.3 Revenue Growth Rate (CAGR %)
9.2.4 Market Share (%)
9.2.5 Product Portfolio Breadth (CBD, THC, Pharmaceuticals)
9.2.6 Geographic Presence (Domestic vs. International)
9.2.7 R&D Investment as % of Revenue
9.2.8 Regulatory Compliance Status
9.2.9 Distribution Network Strength
9.2.10 Clinical Evidence and Certifications

9.3 SWOT Analysis of Top Players

9.4 Pricing Analysis

9.5 Detailed Profile of Major Companies

9.5.1 Bedrocan (Netherlands-based medical cannabis producer)
9.5.2 Canopy Growth Corporation (Canadian cannabis company)
9.5.3 Aurora Cannabis (Canadian cannabis producer)
9.5.4 Tilray (Canadian cannabis and pharmaceutical company)
9.5.5 Cronos Group (Canadian cannabis company)
9.5.6 GlaxoSmithKline (Pharmaceutical company with cannabinoid research)
9.5.7 Insys Therapeutics (Cannabinoid-based pharmaceutical developer)
9.5.8 Zynerba Pharmaceuticals (CBD-focused pharmaceutical company)
9.5.9 Charlotte's Web Holdings (CBD product manufacturer)
9.5.10 Elixinol Global (CBD and hemp product company)
9.5.11 Kalytera Biosciences (Cannabinoid therapeutic developer)
9.5.12 Organigram Holdings (Canadian cannabis producer)
9.5.13 Aphria Inc. (Canadian cannabis company)
9.5.14 Medical Marijuana Inc. (Cannabis and CBD company)
9.5.15 Curaleaf (Cannabis retailer and producer)

10. Saudi Arabia medical cannabis market End-User Analysis

10.1 Procurement Behavior of Key Ministries

10.1.1 Ministry of Health
10.1.2 Ministry of Agriculture
10.1.3 Ministry of Commerce
10.1.4 Others

10.2 Corporate Spend on Infrastructure & Energy

10.2.1 Healthcare Facilities
10.2.2 Research Laboratories
10.2.3 Distribution Networks
10.2.4 Others

10.3 Pain Point Analysis by End-User Category

10.3.1 Healthcare Providers
10.3.2 Patients
10.3.3 Researchers
10.3.4 Others

10.4 User Readiness for Adoption

10.4.1 Awareness Levels
10.4.2 Training Needs
10.4.3 Infrastructure Readiness
10.4.4 Others

10.5 Post-Deployment ROI and Use Case Expansion

10.5.1 Cost Savings
10.5.2 Improved Patient Outcomes
10.5.3 Scalability of Solutions
10.5.4 Others

11. Saudi Arabia medical cannabis market Future Size, 2025-2030

11.1 By Value

11.2 By Volume

11.3 By Average Selling Price


Go-To-Market Strategy Phase

1. Whitespace Analysis + Business Model Canvas

1.1 Market Gaps Identification

1.2 Business Model Development


2. Marketing and Positioning Recommendations

2.1 Branding Strategies

2.2 Product USPs


3. Distribution Plan

3.1 Urban Retail Strategies

3.2 Rural NGO Tie-ups


4. Channel & Pricing Gaps

4.1 Underserved Routes

4.2 Pricing Bands


5. Unmet Demand & Latent Needs

5.1 Category Gaps

5.2 Consumer Segments


6. Customer Relationship

6.1 Loyalty Programs

6.2 After-sales Service


7. Value Proposition

7.1 Sustainability

7.2 Integrated Supply Chains


8. Key Activities

8.1 Regulatory Compliance

8.2 Branding

8.3 Distribution Setup


9. Entry Strategy Evaluation

9.1 Domestic Market Entry Strategy

9.1.1 Product Mix
9.1.2 Pricing Band
9.1.3 Packaging

9.2 Export Entry Strategy

9.2.1 Target Countries
9.2.2 Compliance Roadmap

10. Entry Mode Assessment

10.1 JV

10.2 Greenfield

10.3 M&A

10.4 Distributor Model


11. Capital and Timeline Estimation

11.1 Capital Requirements

11.2 Timelines


12. Control vs Risk Trade-Off

12.1 Ownership vs Partnerships


13. Profitability Outlook

13.1 Breakeven Analysis

13.2 Long-term Sustainability


14. Potential Partner List

14.1 Distributors

14.2 JVs

14.3 Acquisition Targets


15. Execution Roadmap

15.1 Phased Plan for Market Entry

15.1.1 Market Setup
15.1.2 Market Entry
15.1.3 Growth Acceleration
15.1.4 Scale & Stabilize

15.2 Key Activities and Milestones

15.2.1 Milestone Planning
15.2.2 Activity Tracking

Research Methodology

ApproachModellingSample

Phase 1: Approach1

Desk Research

  • Analysis of existing literature on medical cannabis regulations in Saudi Arabia
  • Review of market reports and white papers from health organizations and industry bodies
  • Examination of demographic and health statistics from the Saudi Ministry of Health

Primary Research

  • Interviews with healthcare professionals specializing in pain management and palliative care
  • Surveys targeting pharmacists and dispensary operators regarding cannabis product availability
  • Focus groups with patients and caregivers to understand perceptions and needs

Validation & Triangulation

  • Cross-validation of findings with international medical cannabis market trends
  • Triangulation of data from regulatory bodies, healthcare providers, and patient feedback
  • Sanity checks through expert panel discussions with industry veterans

Phase 2: Market Size Estimation1

Top-down Assessment

  • Estimation of potential market size based on population health statistics and chronic illness prevalence
  • Analysis of government healthcare expenditure and its allocation towards alternative therapies
  • Incorporation of projected growth rates in the medical cannabis sector globally

Bottom-up Modeling

  • Estimation of product demand based on patient population and treatment protocols
  • Cost analysis of medical cannabis products and their pricing strategies in the local market
  • Volume estimates derived from anticipated patient uptake and prescription rates

Forecasting & Scenario Analysis

  • Multi-factor regression analysis incorporating socio-economic factors and healthcare policy changes
  • Scenario modeling based on varying levels of regulatory acceptance and market entry of new products
  • Development of baseline, optimistic, and pessimistic market forecasts through 2030

Phase 3: CATI Sample Composition1

Scope Item/SegmentSample SizeTarget Respondent Profiles
Healthcare Professionals150Doctors, Nurses, Pain Management Specialists
Pharmacy Sector100Pharmacists, Pharmacy Managers
Patient Perspectives120Chronic Pain Patients, Caregivers
Regulatory Bodies50Health Policy Makers, Regulatory Officials
Industry Experts80Market Analysts, Cannabis Industry Consultants

Frequently Asked Questions

What is the current value of the medical cannabis market in Saudi Arabia?

The Saudi Arabia medical cannabis market is valued at approximately USD 302 million. This valuation reflects the increasing acceptance of cannabis for medical purposes and the government's initiatives to regulate and promote its use.

What are the main derivatives of medical cannabis available in Saudi Arabia?

Which medical conditions are most commonly treated with cannabis in Saudi Arabia?

What are the growth drivers for the medical cannabis market in Saudi Arabia?

Other Regional/Country Reports

Indonesia Medical Cannabis Market Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

Malaysia Medical Cannabis Market Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

KSA Medical Cannabis Market Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

APAC Medical Cannabis Market Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

SEA Medical Cannabis Market Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

Vietnam Medical Cannabis Market Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

Other Adjacent Reports

Japan CBD Products Market

Qatar THC Products Market

Egypt Cannabinoid Pharmaceuticals Market

Oman Chronic Pain Management Market

Thailand Epilepsy Treatment Market

Oman Cancer Therapeutics Market

Kuwait Alternative Medicine Market

GCC greece nutraceuticals market report Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030Saudi Arabia biotechnology market Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025–2030Saudi Arabia Herbal Supplements Market Outlook to 2030

Why Buy From Us?

Refine Robust Result (RRR) Framework
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follow Robust, Refine and Result (RRR) methodology. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents' facts and opinions, and Result for presenting data with story.

Our Reach Is Unmatched
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Shifting the Research Paradigm
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

More Insights-Better Decisions
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Transparency and Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

Round the Clock Support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Clients Choose Us?

400000+
Reports in repository
150+
Consulting projects a year
100+
Analysts
8000+
Client Queries in 2022